AbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...
Read moreThe investment will be used to complete three phase II clinical trials in which the efficacy of its most advanced products is being studied, namely PBF-680 in patients with chronic obstructive pulmona...
Read moreMiMARK Diagnostics, S.L. a pioneering femtech spin-off from the Vall d'Hebron Research Institute (VHIR), has successfully raised €4.22 million as seed round stage. The substantial investment will dr...
Read moreStereodive Medical es una empresa que nace con una sólida experiencia en el desarrollo de soluciones de software de post-procesado de imágenes. Creemos que aporta un producto innovador, StereoDiver,...
Read moreSara Secall, a chemistry graduate with a master’s degree in environmental science and an MBA, is the current partner and director of investments in Life Sciences at Inveready, a Venture Capital (VC)...
Read moreConnecta Therapeutics has closed a €1.7 million round of investment led by Inveready that will allow the company to take its first drug through to phase IIa clinical trials in patients who have frag...
Read moreThe biotech company Oxolife, created to develop a new treatment to improve the female fertility rate, completed its first funding round by raising 5,000,000 euros in an investment led by Inveready Ass...
Read moreThe biopharmaceutical company Ability Pharmaceuticals SL announced today that it has been awarded €5 million blended financing from the Horizon Europe, European Innovation Council (EIC) Accelerator ...
Read moreXOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for $10.0 million from Palobiofarma S.L.One of the asse...
Read moreEl importe de la ronda asciende a 1,85 millones de euros, destinados a los proyectos de I&D en curso sobre Enfermedad Inflamatoria Intestinal, psoriasis, enfermedades autoinmunes y tumores sólidos. L...
Read moreCon una capitalización bursátil de 16 millones de euros, AB-Biotics buscaba la inyección de recursos para sostener su crecimiento. La empresa de Sant Cugat del Vallès está inmersa en un “exhaus...
Read moreLa ronda avanzará un primer candidato a ensayos clínicos para la leucemia mieloide aguda (LMA) en pacientes definidos como no aptos o “unfit”, es decir, mayores de 60 años cuyo estado de salud ...
Read more